NY-ESO-1 peptide–HLA class I complex (NY-ESO-1/HLA)

NY-ESO-1 (Cancer-Testis Antigen 1B) is a highly immunogenic protein typically expressed only in testicular germ cells and certain placental tissues, making it an ideal tumor-specific target [UniProt P12023]. In various malignancies, such as synovial sarcoma and melanoma, NY-ESO-1 is aberrantly re-expressed and processed into peptides that are presented on the cell surface by HLA class I molecules [NCI Drug Dictionary]. The specific complex of the NY-ESO-1 peptide (predominantly the SLLMWITQC epitope) and HLA-A*02:01 is the primary target for engineered T-cell receptor (TCR) therapies [Journal of Clinical Oncology, 2024]. Unlike CAR-T cells that recognize surface proteins, TCR-based therapies can target this intracellularly derived peptide-MHC complex, expanding the range of targetable tumor antigens [Nature Reviews Drug Discovery]. Therapeutic interventions include TCR-engineered T cells (TCR-T) and bispecific TCR molecules that redirect endogenous T cells to the tumor site [Adaptimmune Therapeutics]. The recent FDA approval of afamitresgene autoleucel (Tecelra) validates this complex as a clinically actionable target for solid tumors [FDA.gov, 2024]. Patient selection for these therapies requires screening for both the specific HLA genotype and the presence of NY-ESO-1 expression in tumor biopsies [GSK Oncology]. While generally safe due to restricted normal tissue expression, potential risks include cytokine release syndrome and off-target reactivity if the TCR cross-reacts with similar self-peptides [Frontiers in Immunology].

Other names

CTAG1B-HLA complexNew York esophageal squamous cell carcinoma 1 peptide-MHC complexNY-ESO-1/HLA-A*02:01NY-ESO-1 pMHC

The mechanism involves the recognition of the NY-ESO-1 peptide presented by HLA class I molecules by an engineered or endogenous T-cell receptor (TCR). This binding event triggers the formation of an immunological synapse, leading to the release of perforin and granzymes, and the secretion of pro-inflammatory cytokines (e.g., IFN-gamma, TNF-alpha), which collectively result in the targeted destruction of the tumor cell [Nature Reviews Cancer].